Related Experiment Videos
Pulmonary amyloidosis in hematological disorders
1Claude Bernard University, Department of Respiratory Medicine-Reference Center for Orphan Pulmonary Diseases, Louis Pradel University Hospital, Lyon Bron, France. jean-francois.cordier@chu-lyon.fr
Seminars in Respiratory and Critical Care Medicine
|November 4, 2005
Summary
Amyloidosis involves abnormal protein deposits in tissues, causing organ damage. Pulmonary amyloidosis can affect lungs, leading to respiratory issues, with treatment focusing on underlying causes.
Area of Science:
- Pulmonary Medicine
- Hematology
- Pathology
Background:
- Amyloidosis is characterized by beta-sheet fibril protein deposits.
- AL amyloidosis originates from immunoglobulin-producing plasma cells.
- Pulmonary amyloidosis presents as systemic or localized disease.
Purpose of the Study:
- To define amyloidosis and its manifestations in the lungs.
- To describe the clinical presentation and treatment of pulmonary amyloidosis.
- To evaluate treatment strategies for systemic amyloidosis affecting the lungs.
Main Methods:
- Review of amyloidosis definition and diagnostic features (Congo red staining, birefringence).
- Classification of pulmonary amyloidosis (systemic vs. localized, interstitial vs. nodular).
- Discussion of treatment approaches for systemic and tracheobronchial amyloidosis.
Main Results:
- Pulmonary interstitial amyloidosis is often asymptomatic unless severe.
- Localized forms include nodular amyloidosis and peritumoral deposits.
- Tracheobronchial amyloidosis causes airway stenosis and requires laser treatment.
- Systemic amyloidosis treatment targets clonal plasma cells.
Conclusions:
- Pulmonary amyloidosis has diverse presentations and impacts.
- Treatment efficacy for diffuse pulmonary amyloidosis remains unestablished.
- Management strategies vary based on amyloidosis type and location.